StockData

Arrowhead Pharmaceuticals vs Kiniksa Pharmaceuticals International

ARWR and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARWR and KNSA compare

Kiniksa Pharmaceuticals International is the larger company, worth 2.5 times as much as Arrowhead Pharmaceuticals ($14.9B against $6.1B).

Kiniksa Pharmaceuticals International grew revenue faster over the last twelve months (58.2% versus 16.8% for Arrowhead Pharmaceuticals).

Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −47.8% at Arrowhead Pharmaceuticals.

Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARWRKNSA
Size and price
Market cap$6.1B$14.9B
Share price$42.99$95.11
Change, 1 year4.2%136%
Change, 5 years−40.3%716%
Beta (5Y)1.570.15
Employees711366
StockData Score
Total score514 (better)
Valuation score00
Growth score24 (better)
Performance score24 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–73.2×
P/S9.1× (better)15.8×
P/B13.0× (better)21.0×
EV/EBITDA–109×
P/FCF–75.8×
FCF yield−1.2%1.3% (better)
Fair value$31.89$16.72
Margin of safety−34.8% (better)−469%
Growth
Revenue growth (TTM)16.8%58.2% (better)
Revenue growth, 5Y average56.6%–
Net income growth (TTM)–205%
EPS growth (TTM)–189%
Profitability
Gross margin–90.2%
Operating margin−33.8%13.8% (better)
Net margin−47.8%11.6% (better)
FCF margin−11.2%20.8% (better)
Return on equity−64.8%17.6% (better)
Return on invested capital–60.2%
Financial health
Debt / equity–0.00
Interest coverage−2.4×–
Current ratio5.90 (better)3.91
Altman Z-score1.6934.40 (better)
Piotroski F-score58 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.6%29.9%
Held by insiders4.0%5.1%
Insider net buying, 12 months−$36.9M (better)−$122M
Short interest, % of float8.5%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.